ConductScience.org, home

Comparison · NCT03238235-ef5cc6e4

Givinostat vs Placebo: Percentage of Patients With < 10% Worsening in 6MWT After 12 Months of Treatment.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Givinostat vs Placebo: Percentage of Patients With < 10% Worsening in 6MWT After 12 Months of Treatment. Trial comparisons, record NCT03238235-ef5cc6e4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03238235-ef5cc6e4

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2060.1030.368wilson
Risk in group 20.05880.01050.27wilson
Risk difference, group 1 minus group 20.147-0.08750.316newcombe hybrid score
Risk ratio, group 1 over group 23.50.46826.2log
Odds ratio, group 1 over group 24.150.46736.9log
Number needed to treat, for one more participant with the outcome on Givinostat than on Placebo6.8from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1GivinostatGivinostat oral suspension (10 mg/mL) twice daily in a fed state~Givinostat: suspension of Givinostat (10 mg/mL)734OG000
Group 2PlaceboPlacebo oral suspension (10 mg/mL) twice daily in a fed state~Placebo: suspension manufactured to mimic Givinostat117OG001

Outcome

Type
SECONDARY
Title
Percentage of Patients With < 10% Worsening in 6MWT After 12 Months of Treatment.
Description
Percentage of patients with \< 10% worsening in 6-Minute Walking Test after 12 months of treatment with Givinostat comparing to placebo patients.
Time frame
after 12 months of treatment (Visit 11)
Population
Intent-To-Treat Analysis (ITT) Set: all patients assigned treatment by randomization who received at least one dose of study medication. According to the intent to treat principle, patients were analyzed according to the treatment assigned. Patients with missing data such that \<10% worsening cannot be determined are included in the analysis as having worsened

Source ClinicalTrials.gov

Trial

Title
Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy
NCT number
NCT03238235
Phases
PHASE2
Conditions
Becker Muscular Dystrophy
Interventions
Givinostat, Placebo
Lead sponsor
Italfarmaco
Results first posted
2024-11-18

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03238235-ef5cc6e4